[TITLE]HighTower Advisors LLC Acquires 48,247 Shares of American Healthcare REIT, Inc. $AHR:
[TEXT]
HighTower Advisors LLC raised its holdings in shares of American Healthcare REIT, Inc. (NYSE:AHR – Free Report) by 68.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 118,230 shares of the company’s stock after purchasing an additional 48,247 shares during the period. HighTower Advisors LLC owned 0.08% of American Healthcare REIT worth $3,582,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of AHR. Invesco Ltd. raised its stake in American Healthcare REIT by 1,543.1% in the first quarter. Invesco Ltd. now owns 5,022,455 shares of the company’s stock worth $152,180,000 after buying an additional 4,716,792 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of American Healthcare REIT by 22.4% in the 1st quarter. Vanguard Group Inc. now owns 18,795,192 shares of the company’s stock valued at $569,494,000 after acquiring an additional 3,437,861 shares during the period. Nuveen LLC bought a new position in shares of American Healthcare REIT in the 1st quarter worth $68,097,000. Northern Trust Corp raised its position in shares of American Healthcare REIT by 99.0% in the 4th quarter. Northern Trust Corp now owns 1,732,882 shares of the company’s stock worth $49,249,000 after acquiring an additional 861,882 shares in the last quarter. Finally, Waterfront Capital Partners LLC purchased a new stake in shares of American Healthcare REIT during the 4th quarter worth $15,066,000. Hedge funds and other institutional investors own 16.68% of the company’s stock.

Get American Healthcare REIT alerts:

Insider Buying and Selling at American Healthcare REIT

In other news, CIO Stefan K.L. Oh sold 3,860 shares of the firm’s stock in a transaction dated Monday, June 30th. The stock was sold at an average price of $36.10, for a total value of $139,346.00. Following the completion of the transaction, the executive directly owned 95,671 shares in the company, valued at $3,453,723.10. This trade represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.92% of the company’s stock.

American Healthcare REIT Stock Up 1.7%

NYSE:AHR opened at $42.4430 on Friday. The company has a current ratio of 0.48, a quick ratio of 0.48 and a debt-to-equity ratio of 0.41. American Healthcare REIT, Inc. has a twelve month low of $19.53 and a twelve month high of $42.54. The company has a market cap of $7.15 billion, a PE ratio of -192.92, a P/E/G ratio of 2.13 and a beta of 1.08. The company’s 50 day moving average is $37.91 and its two-hundred day moving average is $33.42.

American Healthcare REIT (NYSE:AHR – Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.40 by $0.02. The business had revenue of $542.50 million during the quarter, compared to the consensus estimate of $539.49 million. American Healthcare REIT had a negative net margin of 1.56% and a negative return on equity of 1.43%. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.33 earnings per share. American Healthcare REIT has set its FY 2025 guidance at 1.640-1.680 EPS. Analysts anticipate that American Healthcare REIT, Inc. will post 1.41 EPS for the current year.

American Healthcare REIT Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, July 18th. Shareholders of record on Monday, June 30th were paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 2.4%. The ex-dividend date was Monday, June 30th. American Healthcare REIT’s payout ratio is presently -454.55%.

Analyst Ratings Changes

A number of brokerages have commented on AHR. KeyCorp boosted their target price on shares of American Healthcare REIT from $34.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, June 11th. Royal Bank Of Canada boosted their price objective on shares of American Healthcare REIT from $39.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 13th. Baird R W raised shares of American Healthcare REIT to a “strong-buy” rating in a research report on Thursday, July 17th. JMP Securities lifted their price target on shares of American Healthcare REIT from $40.00 to $45.00 and gave the stock a “market outperform” rating in a report on Monday, August 11th. Finally, Scotiabank started coverage on American Healthcare REIT in a report on Monday, June 30th. They set a “sector outperform” rating and a $42.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $41.11.

Read Our Latest Analysis on American Healthcare REIT

American Healthcare REIT Company Profile

(Free Report)

Formed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value.

Further Reading

Want to see what other hedge funds are holding AHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for American Healthcare REIT, Inc. (NYSE:AHR – Free Report).

Receive News & Ratings for American Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/22/hightower-advisors-llc-acquires-48247-shares-of-american-healthcare-reit-inc-ahr/


[TITLE]Charles Schwab Investment Management Inc. Increases Stock Position in AMN Healthcare Services Inc $AMN:
[TEXT]
Charles Schwab Investment Management Inc. boosted its stake in AMN Healthcare Services Inc (NYSE:AMN – Free Report) by 1.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 904,275 shares of the company’s stock after purchasing an additional 17,064 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in AMN Healthcare Services were worth $22,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Janney Montgomery Scott LLC raised its stake in AMN Healthcare Services by 34.4% in the first quarter. Janney Montgomery Scott LLC now owns 15,145 shares of the company’s stock valued at $370,000 after purchasing an additional 3,880 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in AMN Healthcare Services during the first quarter valued at approximately $592,000. Golden State Wealth Management LLC grew its position in AMN Healthcare Services by 107.0% during the first quarter. Golden State Wealth Management LLC now owns 1,159 shares of the company’s stock valued at $28,000 after acquiring an additional 599 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in AMN Healthcare Services during the first quarter valued at approximately $1,581,000. Finally, GAMMA Investing LLC grew its position in AMN Healthcare Services by 74.9% during the first quarter. GAMMA Investing LLC now owns 5,278 shares of the company’s stock valued at $129,000 after acquiring an additional 2,260 shares during the last quarter. 99.23% of the stock is owned by hedge funds and other institutional investors.

Get AMN Healthcare Services alerts:

AMN Healthcare Services Stock Down 3.1%

Shares of AMN Healthcare Services stock opened at $19.6650 on Friday. The company has a debt-to-equity ratio of 1.51, a quick ratio of 1.00 and a current ratio of 1.00. AMN Healthcare Services Inc has a 52-week low of $14.86 and a 52-week high of $54.01. The stock has a market capitalization of $753.56 million, a price-to-earnings ratio of -2.53 and a beta of 0.10. The company’s 50 day moving average price is $20.07 and its 200-day moving average price is $21.65.

Wall Street Analyst Weigh In

AMN Healthcare Services ( NYSE:AMN Get Free Report ) last issued its earnings results on Thursday, August 7th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.13. AMN Healthcare Services had a negative net margin of 10.75% and a positive return on equity of 11.09%. The firm had revenue of $658.18 million for the quarter, compared to analysts’ expectations of $652.89 million. During the same quarter last year, the business earned $0.98 earnings per share. The business’s revenue was down 11.1% on a year-over-year basis. AMN Healthcare Services has set its Q3 2025 guidance at EPS. Equities research analysts forecast that AMN Healthcare Services Inc will post 1.33 EPS for the current year.

A number of brokerages have commented on AMN. UBS Group reduced their price target on shares of AMN Healthcare Services from $30.00 to $25.50 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th. BMO Capital Markets reduced their price target on shares of AMN Healthcare Services from $27.00 to $22.00 and set an “outperform” rating on the stock in a research report on Monday, August 11th. Finally, JMP Securities reduced their price target on shares of AMN Healthcare Services from $33.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, AMN Healthcare Services currently has an average rating of “Hold” and a consensus price target of $28.25.

Get Our Latest Report on AMN
[Source link]: https://www.etfdailynews.com/2025/08/22/charles-schwab-investment-management-inc-increases-stock-position-in-amn-healthcare-services-inc-amn/


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/citiustech-acquires-health-data-movers-enhances-healthcare-provider-offerings-with-epic-implementation-capabilities]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/sonitor-and-tagnos-announce-strategic-merger-paving-the-way-for-enhanced-healthcare-technology-solutions]

================================================================================

[TITLE]Diversified Healthcare Trust $DHC Shares Bought by Brooklyn Investment Group:
[TEXT]
Brooklyn Investment Group boosted its stake in shares of Diversified Healthcare Trust (NASDAQ:DHC – Free Report) by 296.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,174 shares of the real estate investment trust’s stock after buying an additional 13,588 shares during the quarter. Brooklyn Investment Group’s holdings in Diversified Healthcare Trust were worth $44,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DHC. Chicago Partners Investment Group LLC acquired a new position in Diversified Healthcare Trust during the first quarter worth about $34,000. Deerfield Management Company L.P. Series C acquired a new position in Diversified Healthcare Trust during the fourth quarter worth about $36,000. Boothbay Fund Management LLC purchased a new stake in shares of Diversified Healthcare Trust in the fourth quarter valued at about $41,000. Ground Swell Capital LLC purchased a new stake in shares of Diversified Healthcare Trust in the first quarter valued at about $45,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Diversified Healthcare Trust in the first quarter valued at about $59,000. 75.98% of the stock is currently owned by institutional investors and hedge funds.

Get Diversified Healthcare Trust alerts:

Diversified Healthcare Trust Stock Up 6.7%

Shares of NASDAQ DHC opened at $3.80 on Friday. Diversified Healthcare Trust has a 12-month low of $2.00 and a 12-month high of $4.24. The company has a market capitalization of $917.36 million, a PE ratio of -3.19 and a beta of 2.52. The company has a debt-to-equity ratio of 1.42, a current ratio of 6.35 and a quick ratio of 6.35. The firm’s 50-day moving average is $3.55 and its two-hundred day moving average is $2.98.

Diversified Healthcare Trust Announces Dividend

Diversified Healthcare Trust ( NASDAQ:DHC Get Free Report ) last announced its quarterly earnings results on Monday, August 4th. The real estate investment trust reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. Diversified Healthcare Trust had a negative net margin of 18.83% and a negative return on equity of 14.69%. The company had revenue of $382.71 million for the quarter, compared to the consensus estimate of $382.74 million.

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 14th. Shareholders of record on Monday, July 21st were issued a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Monday, July 21st. Diversified Healthcare Trust’s dividend payout ratio is -3.36%.

Diversified Healthcare Trust Company Profile

(Free Report)

Diversified Healthcare Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Office Portfolio, Senior Housing Operating Portfolio (SHOP), and Non-Segment. The Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants.

Further Reading

Want to see what other hedge funds are holding DHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diversified Healthcare Trust (NASDAQ:DHC – Free Report).

Receive News & Ratings for Diversified Healthcare Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diversified Healthcare Trust and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/24/diversified-healthcare-trust-dhc-shares-bought-by-brooklyn-investment-group/


[TITLE]Kovitz Investment Group Partners LLC Sells 6,586 Shares of iShares U.S. Healthcare ETF $IYH:
[TEXT]
Kovitz Investment Group Partners LLC decreased its position in shares of iShares U.S. Healthcare ETF (NYSEARCA:IYH – Free Report) by 61.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,049 shares of the company’s stock after selling 6,586 shares during the period. Kovitz Investment Group Partners LLC’s holdings in iShares U.S. Healthcare ETF were worth $247,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. MML Investors Services LLC raised its position in iShares U.S. Healthcare ETF by 3.3% in the 4th quarter. MML Investors Services LLC now owns 87,994 shares of the company’s stock valued at $5,127,000 after purchasing an additional 2,828 shares during the last quarter. TD Waterhouse Canada Inc. raised its holdings in shares of iShares U.S. Healthcare ETF by 3.5% in the fourth quarter. TD Waterhouse Canada Inc. now owns 23,950 shares of the company’s stock valued at $1,396,000 after buying an additional 804 shares during the last quarter. MGO One Seven LLC raised its holdings in shares of iShares U.S. Healthcare ETF by 9.8% in the fourth quarter. MGO One Seven LLC now owns 27,454 shares of the company’s stock valued at $1,600,000 after buying an additional 2,451 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management acquired a new position in iShares U.S. Healthcare ETF during the 4th quarter worth
[Source link]: https://www.etfdailynews.com/2025/08/23/kovitz-investment-group-partners-llc-sells-6586-shares-of-ishares-u-s-healthcare-etf-iyh/


[TITLE]HighTower Advisors LLC Acquires 48,247 Shares of American Healthcare REIT, Inc. $AHR:
[TEXT]
HighTower Advisors LLC raised its holdings in shares of American Healthcare REIT, Inc. (NYSE:AHR – Free Report) by 68.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 118,230 shares of the company’s stock after purchasing an additional 48,247 shares during the period. HighTower Advisors LLC owned 0.08% of American Healthcare REIT worth $3,582,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of AHR. Invesco Ltd. raised its stake in American Healthcare REIT by 1,543.1% in the first quarter. Invesco Ltd. now owns 5,022,455 shares of the company’s stock worth $152,180,000 after buying an additional 4,716,792 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of American Healthcare REIT by 22.4% in the 1st quarter. Vanguard Group Inc. now owns 18,795,192 shares of the company’s stock valued at $569,494,000 after acquiring an additional 3,437,861 shares during the period. Nuveen LLC bought a new position in shares of American Healthcare REIT in the 1st quarter worth $68,097,000. Northern Trust Corp raised its position in shares of American Healthcare REIT by 99.0% in the 4th quarter. Northern Trust Corp now owns 1,732,882 shares of the company’s stock worth $49,249,000 after acquiring an additional 861,882 shares in the last quarter. Finally, Waterfront Capital Partners LLC purchased a new stake in shares of American Healthcare REIT during the 4th quarter worth $15,066,000. Hedge funds and other institutional investors own 16.68% of the company’s stock.

Get American Healthcare REIT alerts:

Insider Buying and Selling at American Healthcare REIT

In other news, CIO Stefan K.L. Oh sold 3,860 shares of the firm’s stock in a transaction dated Monday, June 30th. The stock was sold at an average price of $36.10, for a total value of $139,346.00. Following the completion of the transaction, the executive directly owned 95,671 shares in the company, valued at $3,453,723.10. This trade represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.92% of the company’s stock.

American Healthcare REIT Stock Up 1.7%

NYSE:AHR opened at $42.4430 on Friday. The company has a current ratio of 0.48, a quick ratio of 0.48 and a debt-to-equity ratio of 0.41. American Healthcare REIT, Inc. has a twelve month low of $19.53 and a twelve month high of $42.54. The company has a market cap of $7.15 billion, a PE ratio of -192.92, a P/E/G ratio of 2.13 and a beta of 1.08. The company’s 50 day moving average is $37.91 and its two-hundred day moving average is $33.42.

American Healthcare REIT (NYSE:AHR – Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.40 by $0.02. The business had revenue of $542.50 million during the quarter, compared to the consensus estimate of $539.49 million. American Healthcare REIT had a negative net margin of 1.56% and a negative return on equity of 1.43%. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.33 earnings per share. American Healthcare REIT has set its FY 2025 guidance at 1.640-1.680 EPS. Analysts anticipate that American Healthcare REIT, Inc. will post 1.41 EPS for the current year.

American Healthcare REIT Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, July 18th. Shareholders of record on Monday, June 30th were paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 2.4%. The ex-dividend date was Monday, June 30th. American Healthcare REIT’s payout ratio is presently -454.55%.

Analyst Ratings Changes

A number of brokerages have commented on AHR. KeyCorp boosted their target price on shares of American Healthcare REIT from $34.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, June 11th. Royal Bank Of Canada boosted their price objective on shares of American Healthcare REIT from $39.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 13th. Baird R W raised shares of American Healthcare REIT to a “strong-buy” rating in a research report on Thursday, July 17th. JMP Securities lifted their price target on shares of American Healthcare REIT from $40.00 to $45.00 and gave the stock a “market outperform” rating in a report on Monday, August 11th. Finally, Scotiabank started coverage on American Healthcare REIT in a report on Monday, June 30th. They set a “sector outperform” rating and a $42.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $41.11.

Read Our Latest Analysis on American Healthcare REIT

American Healthcare REIT Company Profile

(Free Report)

Formed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value.

Further Reading

Want to see what other hedge funds are holding AHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for American Healthcare REIT, Inc. (NYSE:AHR – Free Report).

Receive News & Ratings for American Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/22/hightower-advisors-llc-acquires-48247-shares-of-american-healthcare-reit-inc-ahr/


[TITLE]Public Sector Pension Investment Board Has $2.35 Million Stock Position in Healthcare Services Group, Inc. $HCSG:
[TEXT]
Public Sector Pension Investment Board grew its holdings in shares of Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report) by 27.6% in the first quarter, Holdings Channel reports. The institutional investor owned 233,034 shares of the business services provider’s stock after acquiring an additional 50,462 shares during the period. Public Sector Pension Investment Board’s holdings in Healthcare Services Group were worth $2,349,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Sterling Capital Management LLC grew its holdings in shares of Healthcare Services Group by 803.4% during the fourth quarter. Sterling Capital Management LLC now owns 2,358 shares of the business services provider’s stock valued at $27,000 after buying an additional 2,097 shares during the last quarter. US Bancorp DE grew its holdings in shares of Healthcare Services Group by 161.4% during the first quarter. US Bancorp DE now owns 8,097 shares of the business services provider’s stock valued at $82,000 after buying an additional 5,000 shares during the last quarter. Bank of Montreal Can acquired a new position in shares of Healthcare Services Group during the fourth quarter valued at
[Source link]: https://www.etfdailynews.com/2025/08/20/public-sector-pension-investment-board-has-2-35-million-stock-position-in-healthcare-services-group-inc-hcsg/

================================================================================

[TITLE]Charles Schwab Investment Management Inc. Buys 227,660 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX:
[TEXT]
Charles Schwab Investment Management Inc. boosted its stake in shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX – Free Report) by 14.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,767,594 shares of the company’s stock after acquiring an additional 227,660 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in AMNEAL PHARMACEUTICALS were worth $14,812,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of AMNEAL PHARMACEUTICALS by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock valued at $132,092,000 after purchasing an additional 920,758 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in AMNEAL PHARMACEUTICALS by 93.8% during the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 89,598 shares of the company’s stock valued at $751,000 after acquiring an additional 43,358 shares during the last quarter. XTX Topco Ltd increased its position in AMNEAL PHARMACEUTICALS by 110.7% during the first quarter. XTX Topco Ltd now owns 82,276 shares of the company’s stock valued at $689,000 after acquiring an additional 43,221 shares during the last quarter. Mackenzie Financial Corp increased its position in AMNEAL PHARMACEUTICALS by 1,281.5% during the first quarter. Mackenzie Financial Corp now owns 168,830 shares of the company’s stock valued at $1,415,000 after acquiring an additional 156,609 shares during the last quarter. Finally, Corton Capital Inc. bought a new position in AMNEAL PHARMACEUTICALS during the first quarter valued at $196,000. 31.82% of the stock is owned by institutional investors.

Get AMNEAL PHARMACEUTICALS alerts:

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of AMNEAL PHARMACEUTICALS in a report on Friday, June 6th. They set a “buy” rating and a $12.00 price target on the stock. Wall Street Zen cut AMNEAL PHARMACEUTICALS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 13th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, AMNEAL PHARMACEUTICALS presently has a consensus rating of “Buy” and a consensus target price of $11.60.

AMNEAL PHARMACEUTICALS Price Performance

Shares of AMRX stock opened at $9.59 on Friday. The company has a market capitalization of $3.01 billion, a P/E ratio of 959.96 and a beta of 1.11. The company’s 50-day simple moving average is $8.38 and its two-hundred day simple moving average is $8.01. AMNEAL PHARMACEUTICALS, INC. has a one year low of $6.68 and a one year high of $9.79.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. On average, research analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling at AMNEAL PHARMACEUTICALS

In related news, EVP Jason B. Daly sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total transaction of $199,100.00. Following the sale, the executive vice president owned 10,606 shares of the company’s stock, valued at $95,984.30. This trade represents a 67.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Nikita Shah sold 71,694 shares of the firm’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $9.29, for a total value of $666,037.26. Following the completion of the sale, the executive vice president directly owned 267,235 shares of the company’s stock, valued at approximately $2,482,613.15. This represents a 21.15% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 456,374 shares of company stock valued at $4,239,042. 26.56% of the stock is currently owned by corporate insiders.

AMNEAL PHARMACEUTICALS Profile

(Free Report)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Featured Stories

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX – Free Report).

Receive News & Ratings for AMNEAL PHARMACEUTICALS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMNEAL PHARMACEUTICALS and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/24/charles-schwab-investment-management-inc-buys-227660-shares-of-amneal-pharmaceuticals-inc-amrx/


[TITLE]11,832 Shares in ACADIA Pharmaceuticals Inc. $ACAD Acquired by Cetera Investment Advisers:
[TEXT]
Cetera Investment Advisers purchased a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,832 shares of the biopharmaceutical company’s stock, valued at approximately $197,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. GF Fund Management CO. LTD. increased its position in shares of ACADIA Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 4,260 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 766 shares in the last quarter. Xponance Inc. increased its position in shares of ACADIA Pharmaceuticals by 14.1% in the first quarter. Xponance Inc. now owns 11,585 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 1,434 shares in the last quarter. Exchange Traded Concepts LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the first quarter worth $29,000. CWM LLC boosted its stake in shares of ACADIA Pharmaceuticals by 50.1% in the first quarter. CWM LLC now owns 5,845 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 1,951 shares during the period. Finally, Virtus Fund Advisers LLC purchased a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at $39,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

Get ACADIA Pharmaceuticals alerts:

ACADIA Pharmaceuticals Price Performance

NASDAQ ACAD opened at $25.74 on Friday. ACADIA Pharmaceuticals Inc. has a 12 month low of $13.40 and a 12 month high of $25.88. The company has a market capitalization of $4.34 billion, a price-to-earnings ratio of 19.35, a price-to-earnings-growth ratio of 6.31 and a beta of 0.70. The company’s fifty day moving average price is $23.02 and its two-hundred day moving average price is $19.71.

Insider Transactions at ACADIA Pharmaceuticals

ACADIA Pharmaceuticals ( NASDAQ:ACAD Get Free Report ) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. The firm had revenue of $264.57 million for the quarter, compared to the consensus estimate of $263.07 million. During the same period in the prior year, the firm posted $0.20 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. As a group, analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.

In other news, Director Laura Brege sold 14,446 shares of the firm’s stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $21.78, for a total value of $314,633.88. Following the transaction, the director directly owned 15,095 shares in the company, valued at approximately $328,769.10. This trade represents a 48.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Mark C. Schneyer sold 22,000 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $25.18, for a total transaction of $553,960.00. Following the completion of the transaction, the executive vice president owned 40,130 shares in the company, valued at approximately $1,010,473.40. The trade was a 35.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 26.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ACAD. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, June 26th. The Goldman Sachs Group upped their target price on shares of ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the company a “sell” rating in a research note on Thursday, August 7th. BMO Capital Markets upped their target price on shares of ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the company an “outperform” rating in a research note on Monday, May 19th. Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 16th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the company from $20.00 to $35.00 in a research note on Wednesday, May 21st. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $28.88.

Get Our Latest Analysis on ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Profile

(Free Report)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

See Also

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report).

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/23/11832-shares-in-acadia-pharmaceuticals-inc-acad-acquired-by-cetera-investment-advisers/


[TITLE]Nuveen LLC Makes New Investment in Tarsus Pharmaceuticals, Inc. $TARS:
[TEXT]
Nuveen LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 264,523 shares of the company’s stock, valued at approximately $13,589,000.

A number of other institutional investors also recently bought and sold shares of TARS. Wells Fargo & Company MN raised its position in Tarsus Pharmaceuticals by 44.1% during the 4th quarter. Wells Fargo & Company MN now owns 57,004 shares of the company’s stock worth $3,156,000 after buying an additional 17,451 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Tarsus Pharmaceuticals during the 4th quarter worth approximately $1,107,000. MetLife Investment Management LLC raised its position in Tarsus Pharmaceuticals by 5.5% during the 4th quarter. MetLife Investment Management LLC now owns 22,678 shares of the company’s stock worth $1,256,000 after buying an additional 1,174 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Tarsus Pharmaceuticals by 92.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 460,773 shares of the company’s stock worth $25,514,000 after buying an additional 221,458 shares during the last quarter. Finally, Voya Investment Management LLC grew its stake in shares of Tarsus Pharmaceuticals by 149.6% during the 4th quarter. Voya Investment Management LLC now owns 30,033 shares of the company’s stock worth $1,663,000 after purchasing an additional 18,000 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

Get Tarsus Pharmaceuticals alerts:

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS opened at $56.56 on Friday. The firm has a market cap of $2.39 billion, a PE ratio of -24.27 and a beta of 0.79. The firm has a fifty day moving average of $43.51 and a 200 day moving average of $45.85. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.21 and a current ratio of 5.26. Tarsus Pharmaceuticals, Inc. has a one year low of $25.14 and a one year high of $57.28.

Wall Street Analysts Forecast Growth

Tarsus Pharmaceuticals ( NASDAQ:TARS Get Free Report ) last announced its earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%.The business had revenue of $102.66 million for the quarter, compared to analyst estimates of $95.81 million. As a group, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

A number of equities research analysts have recently commented on TARS shares. HC Wainwright raised shares of Tarsus Pharmaceuticals to a “buy” rating and set a $72.00 price objective on the stock in a research note on Tuesday, May 27th. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They set an “outperform” rating and a $75.00 price objective on the stock. The Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a “neutral” rating in a research note on Monday, May 5th. Finally, Guggenheim raised their price objective on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Buy” and an average target price of $66.67.

View Our Latest Report on Tarsus Pharmaceuticals

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $50.00, for a total transaction of $300,000.00. Following the transaction, the chief executive officer owned 818,106 shares of the company’s stock, valued at approximately $40,905,300. The trade was a 0.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 8.97% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

(Free Report)

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Read More

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report).

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/22/nuveen-llc-makes-new-investment-in-tarsus-pharmaceuticals-inc-tars/


[TITLE]Invesco Ltd. Has $17.38 Million Stake in Supernus Pharmaceuticals, Inc. $SUPN:
[TEXT]
Invesco Ltd. boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 4.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 530,631 shares of the specialty pharmaceutical company’s stock after buying an additional 22,562 shares during the quarter. Invesco Ltd.’s holdings in Supernus Pharmaceuticals were worth $17,378,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Raiffeisen Bank International AG acquired a new position in Supernus Pharmaceuticals during the fourth quarter worth $25,000. Financial Management Professionals Inc. acquired a new position in Supernus Pharmaceuticals during the first quarter worth $30,000. Versant Capital Management Inc increased its position in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock worth $37,000 after buying an additional 1,109 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at
[Source link]: https://www.etfdailynews.com/2025/08/22/invesco-ltd-has-17-38-million-stake-in-supernus-pharmaceuticals-inc-supn/

================================================================================

[TITLE]Brooklyn Investment Group Makes New Investment in Sana Biotechnology, Inc. $SANA:
[TEXT]
Brooklyn Investment Group purchased a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) during the first quarter, Holdings Channel.com reports. The firm purchased 25,943 shares of the company’s stock, valued at approximately $44,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of SANA. Geode Capital Management LLC boosted its holdings in shares of Sana Biotechnology by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company’s stock worth $5,206,000 after buying an additional 26,601 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Sana Biotechnology by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 62,021 shares of the company’s stock worth $101,000 after buying an additional 20,950 shares in the last quarter. Cerity Partners LLC bought a new position in shares of Sana Biotechnology during the 4th quarter worth approximately $25,000. Renaissance Technologies LLC boosted its holdings in shares of Sana Biotechnology by 1,838.3% during the 4th quarter. Renaissance Technologies LLC now owns 319,818 shares of the company’s stock worth $521,000 after buying an additional 303,318 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Sana Biotechnology during the 4th quarter worth approximately $152,000. 88.23% of the stock is currently owned by institutional investors.

Get Sana Biotechnology alerts:

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SANA. JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley began coverage on Sana Biotechnology in a report on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $8.00.

Sana Biotechnology Stock Down 0.6%

Shares of SANA opened at $3.58 on Friday. Sana Biotechnology, Inc. has a 12-month low of $1.26 and a 12-month high of $7.30. The business’s fifty day moving average is $3.64 and its 200 day moving average is $2.70. The stock has a market cap of $851.36 million, a P/E ratio of -3.38 and a beta of 1.90.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. On average, analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.
[Source link]: https://www.etfdailynews.com/2025/08/24/brooklyn-investment-group-makes-new-investment-in-sana-biotechnology-inc-sana/


[TITLE]Vanguard Group Inc. Reduces Stake in Vir Biotechnology, Inc. $VIR:
[TEXT]
Vanguard Group Inc. lessened its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 2.5% in the first quarter, Holdings Channel reports. The fund owned 12,807,508 shares of the company’s stock after selling 323,127 shares during the quarter. Vanguard Group Inc. owned
[Source link]: https://www.etfdailynews.com/2025/08/24/vanguard-group-inc-reduces-stake-in-vir-biotechnology-inc-vir/


[TITLE]Vir Biotechnology, Inc. $VIR Shares Acquired by Public Sector Pension Investment Board:
[TEXT]
Public Sector Pension Investment Board lifted its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 27.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 292,578 shares of the company’s stock after purchasing an additional 63,284 shares during the period. Public Sector Pension Investment Board’s holdings in Vir Biotechnology were worth $1,896,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. State of Tennessee Department of Treasury increased its position in shares of Vir Biotechnology by 3.2% during the fourth quarter. State of Tennessee Department of Treasury now owns 39,268 shares of the company’s stock worth $288,000 after purchasing an additional 1,227 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Vir Biotechnology by 26.2% during the first quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock worth $68,000 after purchasing an additional 2,171 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Vir Biotechnology by 0.6% during the fourth quarter. Invesco Ltd. now owns 398,772 shares of the company’s stock worth $2,927,000 after buying an additional 2,574 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Vir Biotechnology by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 38,290 shares of the company’s stock worth $248,000 after buying an additional 3,209 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Vir Biotechnology by 5.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 71,332 shares of the company’s stock worth $524,000 after buying an additional 3,506 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Get Vir Biotechnology alerts:

Wall Street Analyst Weigh In

A number of research firms recently issued reports on VIR. Raymond James Financial began coverage on Vir Biotechnology in a report on Friday, July 11th. They set an “outperform” rating on the stock. Needham & Company LLC reissued a “buy” rating and set a $14.00 price target on shares of Vir Biotechnology in a report on Thursday, May 22nd. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $30.25.

Vir Biotechnology Stock Performance

Shares of VIR opened at $4.36 on Thursday. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $14.45. The stock’s 50 day moving average is $5.16 and its two-hundred day moving average is $6.14. The firm has a market capitalization of $605.69 million, a PE ratio of -1.09 and a beta of 1.18.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.38 million. During the same period in the prior year, the firm posted ($1.02) EPS. Vir Biotechnology’s revenue for the quarter was down 60.5% compared to the same quarter last year. On average, sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Insider Buying and Selling

In other Vir Biotechnology news, EVP Mark Eisner sold 6,796 shares of Vir Biotechnology stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $5.47, for a total value of $37,174.12. Following the sale, the executive vice president owned 108,204 shares of the company’s stock, valued at approximately $591,875.88. The trade was a 5.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 22,000 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $4.99, for a total value of $109,780.00. Following the sale, the director directly owned 1,276,391 shares in the company, valued at $6,369,191.09. This trade represents a 1.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 57,582 shares of company stock worth $294,930 in the last ninety days. 16.00% of the stock is owned by corporate insiders.

Vir Biotechnology Company Profile

(Free Report)

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

Read More

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report).

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/21/vir-biotechnology-inc-vir-shares-acquired-by-public-sector-pension-investment-board/

================================================================================

[TITLE]Nuveen LLC Acquires New Holdings in Healthcare Services Group, Inc. $HCSG:
[TEXT]
Nuveen LLC acquired a new stake in Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 1,165,133 shares of the business services provider’s stock, valued at approximately $11,745,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Trail Ridge Investment Advisors LLC lifted its stake in Healthcare Services Group by 4.7% in the 1st quarter. Trail Ridge Investment Advisors LLC now owns 23,233 shares of the business services provider’s stock valued at $234,000 after purchasing an additional 1,048 shares during the last quarter. SummerHaven Investment Management LLC lifted its stake in Healthcare Services Group by 1.8% in the 1st quarter. SummerHaven Investment Management LLC now owns 73,841 shares of the business services provider’s stock valued at $744,000 after purchasing an additional 1,297 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Healthcare Services Group by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,880 shares of the business services provider’s stock valued at $486,000 after acquiring an additional 1,461 shares during the period. North Star Investment Management Corp. increased its position in Healthcare Services Group by 1.8% in the 1st quarter. North Star Investment Management Corp. now owns 102,950 shares of the business services provider’s stock valued at $1,038,000 after acquiring an additional 1,850 shares during the period. Finally, Sterling Capital Management LLC increased its position in Healthcare Services Group by 803.4% in the 4th quarter. Sterling Capital Management LLC now owns 2,358 shares of the business services provider’s stock valued at $27,000 after acquiring an additional 2,097 shares during the period. Institutional investors own 97.97% of the company’s stock.

Get Healthcare Services Group alerts:

Healthcare Services Group Stock Up 3.6%

HCSG opened at $15.77 on Friday. Healthcare Services Group, Inc. has a twelve month low of $9.13 and a twelve month high of $15.80. The company has a fifty day moving average of $14.28 and a 200-day moving average of $12.75. The stock has a market cap of $1.14 billion, a PE ratio of 112.64 and a beta of 0.54.

Analyst Ratings Changes

Healthcare Services Group ( NASDAQ:HCSG Get Free Report ) last posted its quarterly earnings data on Wednesday, July 23rd. The business services provider reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.01. Healthcare Services Group had a net margin of 0.61% and a return on equity of 11.74%. The company had revenue of $458.50 million during the quarter, compared to analysts’ expectations of $450.78 million. During the same period in the prior year, the company posted $0.20 earnings per share. Healthcare Services Group’s revenue for the quarter was up 7.6% compared to the same quarter last year. Healthcare Services Group has set its Q3 2025 guidance at EPS. Sell-side analysts anticipate that Healthcare Services Group, Inc. will post 0.74 EPS for the current fiscal year.

Several equities analysts have issued reports on the stock. Benchmark upped their price target on shares of Healthcare Services Group from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Zacks Research upgraded shares of Healthcare Services Group to a “strong-buy” rating in a research report on Tuesday, August 12th. Robert W. Baird upped their price target on shares of Healthcare Services Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Macquarie upgraded shares of Healthcare Services Group from a “neutral” rating to an “outperform” rating and upped their price target for the company from $15.00 to $16.00 in a research report on Tuesday, July 29th. Finally, Wall Street Zen cut shares of Healthcare Services Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 26th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $16.25.

View Our Latest Analysis on HCSG

Insider Buying and Selling at Healthcare Services Group

In other news, EVP John Christopher Shea sold 21,368 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $13.25, for a total transaction of $283,126.00. Following the completion of the sale, the executive vice president directly owned 32,976 shares in the company, valued at $436,932. This represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.60% of the stock is currently owned by company insiders.

Healthcare Services Group Company Profile

(Free Report)

Healthcare Services Group, Inc provides management, administrative, and operating services to the housekeeping, laundry, linen, facility maintenance, and dietary service departments of nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States. It operates through two segments, Housekeeping and Dietary.

Further Reading

Want to see what other hedge funds are holding HCSG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report).

Receive News & Ratings for Healthcare Services Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthcare Services Group and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/23/nuveen-llc-acquires-new-holdings-in-healthcare-services-group-inc-hcsg/


[TITLE]Charles Schwab Investment Management Inc. Increases Stock Position in AMN Healthcare Services Inc $AMN:
[TEXT]
Charles Schwab Investment Management Inc. boosted its stake in AMN Healthcare Services Inc (NYSE:AMN – Free Report) by 1.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 904,275 shares of the company’s stock after purchasing an additional 17,064 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in AMN Healthcare Services were worth $22,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Janney Montgomery Scott LLC raised its stake in AMN Healthcare Services by 34.4% in the first quarter. Janney Montgomery Scott LLC now owns 15,145 shares of the company’s stock valued at $370,000 after purchasing an additional 3,880 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in AMN Healthcare Services during the first quarter valued at approximately $592,000. Golden State Wealth Management LLC grew its position in AMN Healthcare Services by 107.0% during the first quarter. Golden State Wealth Management LLC now owns 1,159 shares of the company’s stock valued at $28,000 after acquiring an additional 599 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in AMN Healthcare Services during the first quarter valued at approximately $1,581,000. Finally, GAMMA Investing LLC grew its position in AMN Healthcare Services by 74.9% during the first quarter. GAMMA Investing LLC now owns 5,278 shares of the company’s stock valued at $129,000 after acquiring an additional 2,260 shares during the last quarter. 99.23% of the stock is owned by hedge funds and other institutional investors.

Get AMN Healthcare Services alerts:

AMN Healthcare Services Stock Down 3.1%

Shares of AMN Healthcare Services stock opened at $19.6650 on Friday. The company has a debt-to-equity ratio of 1.51, a quick ratio of 1.00 and a current ratio of 1.00. AMN Healthcare Services Inc has a 52-week low of $14.86 and a 52-week high of $54.01. The stock has a market capitalization of $753.56 million, a price-to-earnings ratio of -2.53 and a beta of 0.10. The company’s 50 day moving average price is $20.07 and its 200-day moving average price is $21.65.

Wall Street Analyst Weigh In

AMN Healthcare Services ( NYSE:AMN Get Free Report ) last issued its earnings results on Thursday, August 7th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.13. AMN Healthcare Services had a negative net margin of 10.75% and a positive return on equity of 11.09%. The firm had revenue of $658.18 million for the quarter, compared to analysts’ expectations of $652.89 million. During the same quarter last year, the business earned $0.98 earnings per share. The business’s revenue was down 11.1% on a year-over-year basis. AMN Healthcare Services has set its Q3 2025 guidance at EPS. Equities research analysts forecast that AMN Healthcare Services Inc will post 1.33 EPS for the current year.

A number of brokerages have commented on AMN. UBS Group reduced their price target on shares of AMN Healthcare Services from $30.00 to $25.50 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th. BMO Capital Markets reduced their price target on shares of AMN Healthcare Services from $27.00 to $22.00 and set an “outperform” rating on the stock in a research report on Monday, August 11th. Finally, JMP Securities reduced their price target on shares of AMN Healthcare Services from $33.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, AMN Healthcare Services currently has an average rating of “Hold” and a consensus price target of $28.25.

Get Our Latest Report on AMN
[Source link]: https://www.etfdailynews.com/2025/08/22/charles-schwab-investment-management-inc-increases-stock-position-in-amn-healthcare-services-inc-amn/


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/citiustech-acquires-health-data-movers-enhances-healthcare-provider-offerings-with-epic-implementation-capabilities]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/sonitor-and-tagnos-announce-strategic-merger-paving-the-way-for-enhanced-healthcare-technology-solutions]

================================================================================

